Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 10/20 | 0.50 |
| ▸ | CCKAR | P32238 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238494 | 0.80 | CA2 (0.61) | CA2CNR1CCKAR | |
| SCHEMBL28568569 | 0.77 | CA2 (0.71) | CA2CNR1FLT3KDM4EMAPT | |
| SCHEMBL10568558 | 0.77 | GAA (0.45) | CA2CNR1CCKAR | |
| SCHEMBL30437414 | 0.77 | CA2 (0.66) | CA2CNR1CCKARKDM4E | |
| SCHEMBL11329617 | 0.76 | CA2 (0.56) | CA2CNR1CCKARKDM4EHPGD | |
| SCHEMBL8476923 | 0.76 | CNR1 (0.62) | CA2CNR1CCKARCCKBR | |
| SCHEMBL6918547 | 0.76 | CNR1 (0.62) | CA2CNR1 | |
| SCHEMBL8799150 | 0.76 | CNR1 (0.61) | CA2CNR1CCKARKDM4E | |
| SCHEMBL9569772 | 0.76 | CA2 (0.44) | CA2CNR1CCKARMAPT | |
| SCHEMBL29560278 | 0.74 | CA2 (0.67) | CA2CNR1CCKARFLT3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1335720-A1 | SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | Bayer Aktiengesellschaft (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-6498183-B1 | TREATMENT AND PROPHYLAXIS OF DISORDERS CAUSED BY HERPES VIRUSES, IN PARTICULAR HUMAN CYTOMEGALOVIRUS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-24 | — | — | US | disclosed |
| WO-2002036115-A1 | SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1177171-A1 | SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS | Bayer Aktiengesellschaft (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000066553-A1 | SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | HTR6, SLC6A4, AANAT | CA2 1609/4885CNR1 104/4885CCKAR 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.